Cohort of STEMI Patients 2
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
Hospices Civils de Lyon
300 participants
May 3, 2023
INTERVENTIONAL
Conditions
Summary
ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort). The purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years
- Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
- Management in primary ACT
- Prior oral informed consent followed by signed informed consent as soon as possible.
Exclusion Criteria6
- Diagnosis of STEMI not confirmed on angiography
- Inability to give the subject informed information
- Lack of coverage by a social security scheme
- Obvious contraindication to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (GFR<30 ml/min), known allergy to the contrast medium ....)
- Pregnant woman or woman of childbearing age without effective contraception, breastfeeding woman.
- Deprivation of civil rights (curators, guardianship, safeguard of justice)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1 MRI at 1 month with gadolinium injection
Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
EQ-5D-5L and HAD questionaries at 1 month and 1 year.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05794022